Contact Us | Useful Links | FAQs | Feedback | Sitemap |
 
   
 
An integrated strategy for the advancement of the Drug Holding Company :: The Ministry of Public Business Sector announces :: Holdipharma: Providing medical supplies to the hospitals of the Ministry of Health :: The National Bank and HoldiPharma sign a cooperation protocol :: Medicines Holding: We are not a party to the crisis of high alcohol prices ... ::
 
 
Company Details
Company Name   Website
Memphis   www.memphis.com.eg
     
Description

   Memphis Co. for Pharmaceutical and Chemical Industries was founded in April 1940 during World War II in consequence to the appearance of huge shortage of  medicine in Egypt as it was out sourced totally from the European countries at that time.

Starting from the beginning of this war till it ends, the company began to build its primary factory in Zeiton district and tried to equip it with the latest automatic machines and scientific devices in accordance to the latest automation in the pharmaceutical industry at that time.

To apply the new development pursued by  Memphis Company, it was an urgent decision to expand horizontally and transfer the facilities with all the manufacturing sites to another industrial area as large as 16 acres area in Amirya district with the evolving of quality system guidelines in the field of pharmaceutical manufacturing.

The company has built the first sterile area in the Middle East for the production of sterile ampoules and ointments beside establishing a highly sophisticated facility for medicinal plant extracts that were exported to several countries in Asia, Europe, America and Canada, in addition to production of various pharmaceutical dosage forms such as tablets, capsules, syrups, ointments, creams , suppositories and veterinary products.

Memphis Co. now is an Egyptian joint venture company, 60% of the working capital is state-owned by Holding Company and the rest 40% is owned as public shares by a number of shareholders and part of it is owned by a labor union of the company.

The company owns three patency's certificates for its three unique extracts produced by the company (Amodin, amidine, Khellin) as well as three patent inventions for the treatment of patients with vitiligo, psoriasis and urinary tract complications.

The company's products and the facility daily systems are continuously subjected to complete quality control monitoring system to control all the steps of production and that includes the latest calibration schedule for all the devices and tools used during various operating stages. Memphis Company contributes to the national project scheduled by the Egyptian MOH for the treatment of liver diseases (virus C) by presenting "Pegferon" the main similar to the patent one long-acting interferon.

The company's products are mainly introduced from the Egyptian export market with a large number of unique products as well as Memphis got the right of manufacturing a large number of under-licensed pharmaceutical products owned by many international companies because of its famouslong and well-trained expertise and unique capabilities in the field of pharmaceutical Industry.

products company catalog

download

products company profile

download

Board Members:

Dr/ Bassem mohammed abd allaha abd elhamayd                                              Managing Director

Dr/Assam sadek  mohamed sadek                                                                      Chairman Of The Board 

Mr/ Asama adward  khalil                                                                                      Executive Member

Mr/ Tarek Mahros Slmaan                                                                                      Executive Member

Mr/ Osama ghneemy tantawy                                                            Acting as representative of the shareholders

Mr/ Saleem mohamed saleem                                                            Acting as representative of the shareholders

  

 Audit Committee:

 Dr/ Essam sadek                                                                                 Director

Dr/ Osama edward  khalel                                                                    Member

Mr/ Ahmed mohamed abd elmeged                                                       Member

 

 

Company Main Indicators (in thousands of Egyptian Pounds)

Indicator 2017-2018 2018-2019 2019-2020
Net Operating Revenue 343356 366845 490097605
Interest Expenses 794 1695 0
Net Income (46736) (25378) 17408590
Net Equity (34133) (66109) 78864613
Working Capital (83883) (113125) (137435784)
Total Investment 375244 342754 377413278
Salaries 105996 108215 120799897
Number of workers 1626 1544 1478

       
       
       
       
       
       
       
       
       
     
Image Gallery
   
     
Related Links
Affiliates
   
Joint Venture
   
   
   
   
 
 
     
  Copyright © 2009 HOLDIPHARMA. All rights reserved.         Terms of Use | Privacy Statement | Disclaimer |